Forte Research Systems, Inc.

Forte Research Systems, Inc. specializes in developing integrated technology solutions and services for efficient clinical trial management, catering to academic medical centers and healthcare organizations globally. Founded in 2000 and headquartered in Madison, US, Forte Research Systems, Inc. offers a comprehensive suite of tools for clinical trial management.

The company has engaged in two deals, with the most recent occurring on September 5, 2019, when Advarra, Inc. acquired Forte from Primus Capital. Details of the transaction were not disclosed. Forte Research Systems provides an integrated suite of technology and services focused on clinical trial management.

Key offerings include the OnCore Clinical Trial Management System (CTMS) for streamlining operations, compliance, and data management at academic medical centers and cancer centers. Their Advarra eRegulatory System enhances regulatory compliance through a paperless process, while electronic consent and data capture systems improve patient engagement and data collection across various research environments. The company serves over 3,500 institutions, including hospitals and academic medical centers primarily across the United States and in international markets. Forte Research Systems operates on a B2B model, predominantly working with clinical research organizations (CROs), academic institutions, and healthcare organizations through subscription-based services.

Clients generally enter long-term contracts for access to its tools, promoting adherence to regulatory standards. Pricing structures for its flagship products, OnCore and eReg, are tiered based on organizational size and needs, with one-time fees for setup and training and ongoing subscription charges supporting the continued use of these technologies. Forte Research Systems plans to leverage its recent acquisition by Advarra, Inc. to enhance its product offerings and expand its market reach.

The company is focused on developing new products to streamline clinical trial processes, with anticipated features expected to launch by late 2020. Additionally, Forte aims to expand its presence in international markets, targeting Europe and Asia by 2021. Recent funding will support these initiatives, particularly in product development and market penetration efforts.